
Novartis, Amgen in Legal Dispute Over Migraine Partnership
Amgen issued a notice of termination of its migraine collaboration agreements with Novartis, against which Novartis filed a lawsuit in response.
On April 4, 2019, Novartis announced a legal dispute with Amgen regarding the companies’ migraine collaboration agreements. On April 2, 2019, Amgen issued a notice of termination of its migraine collaboration agreements with Novartis based on an alleged material breach, which Novartis disputes. To prevent Amgen’s attempt to end the collaboration, Novartis has filed a lawsuit asking a court to confirm that Amgen cannot legally terminate the agreements. The agreements will remain in force until a final and binding court decision is made regarding termination.
The dispute revolves around Amgen’s Aimovig (erenumab), a preventive treatment for migraine. The drug, approved by FDA in
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.